Which Factors Will Push The Darbepoetin Alfa (Aranesp) Market To Achieve $7.37 Billion By 2029?
Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
#What CAGR And Valuation Are Anticipated For The Darbepoetin Alfa (Aranesp) Market?#_x000D_
In the past few years, the market size for darbepoetin alfa (aranesp) has been gradually expanding. The market is projected to rise from $5.81 billion in 2024 to $6.06 billion in 2025, with a compound annual growth rate (CAGR) of 4.2%. This growth during the historical period can be credited to enhancements in anemia treatment, the increased demand for erythropoiesis-stimulating agents (ESAs), innovations in biopharmaceuticals, clinical approval, and better patient results._x000D_
_x000D_
The market size of darbepoetin alfa (aranesp) is anticipated to experience robust growth in the upcoming years. The market is projected to expand to “$7.37 billion by 2029,” growing at a compound annual growth rate (CAGR) of 5.0%. The estimated growth for this period can be attributed to factors like healthcare reimbursement policies, improved awareness and education, the advancement of healthcare infrastructure, increased demand for renal care, and an older population. Some of the significant trends expected during this period include penetration into the global market, the integration of digital health, personalized treatment strategies, the adoption of biosimilars, and the development of long-acting formulations._x000D_
_x000D_
#Get A Free Sample Of The Report:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=12171&type=smp_x000D_
_x000D_
#What Growth-Enabling Forces Are Impacting The Darbepoetin Alfa (Aranesp) Market?#_x000D_
The escalating occurrence of chronic illnesses is projected to stimulate the expansion of the darbepoetin alfa industry in the long run. Chronic disease is a type of ailment that persists for at least three months and can potentially worsen over time. Darbepoetin alfa is a treatment for an array of such chronic conditions, including being beneficial in reversing anemia brought about by chemotherapy in cancer patients. For example, in June 2024, the Australian Institute of Health and Welfare – an Australian Government statutory body, recorded that chronic disorders resulted in 171,500 fatalities in 2022, accounting for 90% of all deaths at a rate of 659 per 100,000 people. While the age-standardised mortality rate due to chronic diseases dipped to 448 per 100,000 in 2020, it climbed to 459 in 2021 and 490 in 2022. As such, the escalating occurrence of chronic diseases is fuelling the expansion of the darbepoetin alfa industry._x000D_
_x000D_
#What Is The Segment Breakdown Of The Darbepoetin Alfa (Aranesp) Market?#_x000D_
The darbepoetin alfa (aranesp) market covered in this report is segmented – _x000D_
_x000D_
1) By Type: Epogen, Procrit, Aranesp, Other Types_x000D_
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy_x000D_
3) By Application: Patients With Chronic Kidney Disease, Patients With Cancer, Other Applications_x000D_
_x000D_
Subsegments:_x000D_
1) By Epogen: Standard Formulations, Enhanced Formulations _x000D_
2) By Procrit: Standard Formulations, Biosimilars _x000D_
3) By Aranesp: Single-Dose Vials, Multi-Dose Vials _x000D_
4) By Other Types: Combination Therapies, Alternative Erythropoiesis-Stimulating Agents _x000D_
_x000D_
#How Are Global Trends Impacting The Development Of The Darbepoetin Alfa (Aranesp) Market?#_x000D_
A significant trend emerging in the darbepoetin alfa market is the implementation of product innovations. Top-notch firms in the darbepoetin alfa market are utilizing novel technologies to maintain their market stance. As an example, GlaxoSmithKline Ltd., a pharmaceutical and biotech company based in the UK, in February 2023, launched a product approved by the US Food and Drug Administration (FDA), Jesduvroq (daprodustat). Daprodustat, also known as recombinant human erythropoietin (rhEPO), darbepoetin alfa or epoetin alfa, is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor. This drug is used as a once-day treatment for anemia caused by chronic kidney disease (CKD) in individuals who have been undergoing dialysis for a minimum of four months._x000D_
_x000D_
#Which Companies Are Contributing Significantly To The Darbepoetin Alfa (Aranesp) Market Growth?#_x000D_
Major companies operating in the darbepoetin alfa (aranesp) market include Johnson & Johnson, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Biocon Ltd., Reliance Life Sciences, Torrent Pharmaceuticals Ltd., 3SBio Inc., Cadila Healthcare Ltd., Dong-A ST Co. Ltd., Chong Kun Dang Holdings, Hetero Drugs Ltd., Intas Pharmaceuticals Ltd., Avesthagen Pharma, Stada Arzneimittel AG, Ranbaxy Laboratories Ltd., Sandoz International GmbH, Shandong Kexing Bioproducts Co. Ltd., Kyowa Kirin Co. Ltd., Polifarma S.p.A. _x000D_
_x000D_
#Access The Complete Report Here:#_x000D_
_x000D_
#Which Region Is Leading Innovation In The Darbepoetin Alfa (Aranesp) Market?#_x000D_
North America was the largest region in the darbepoetin alfa (Aranesp) market in 2024. The regions covered in the darbepoetin alfa (Aranesp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Customize Your Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=12171&type=smp_x000D_
_x000D_
#About The Business Research Company:#_x000D_
_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
